QR код

Paltusotine versus octreotide: different effects on radioligand uptake in neuroendocrine tumours

Objective: Somatostatin receptor analogues are well-established in the treatment of metastatic gastro-enteropancreatic neuroendocrine tumours (GEP-NETs), especially for symptom control in patients with the carcinoid syndrome, and to control tumour growth. However, they need to be discontinued before...

Повний опис

Збережено в:
Автори: Katharina Wang, Christoph J Auernhammer, Simon Lindner, Mathias Zacherl, Rudolf A Werner, Julian Maurer, Lea Peischer, Julia Hamati, Maximilian P Hungbauer, Thomas Knösel, Astrid Reul, Elena Kuzmenko, Diana Vetter, José Oberholzer, Umberto Maccio, Felix Beuschlein, Martin Reincke, Constanze Hantel, Karel Pacak, Ashley B Grossman, Kathrin Zitzmann, Svenja Nölting
Формат: Artigo
Мова:Inglês
Опубліковано: Bioscientifica 2025-10-01
Серія:Endocrine Oncology
Предмети:
paltusotine
octreotide
somatostatin analogue
neuroendocrine tumour
peptide receptor radionuclide therapy
prrt
Онлайн доступ:https://eo.bioscientifica.com/view/journals/eo/5/1/EO-25-0041.xml
Теги: Додати тег
Немає тегів, Будьте першим, хто поставить тег для цього запису!

Схожі ресурси